Previous Close | 3.9200 |
Open | 3.9000 |
Bid | 0.0000 x 4000 |
Ask | 0.0000 x 800 |
Day's Range | 3.9000 - 4.1437 |
52 Week Range | 3.0500 - 22.9100 |
Volume | |
Avg. Volume | 839,919 |
Market Cap | 636.383M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.9390 |
Earnings Date | Nov 15, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 26.31 |
– Strong execution across atai’s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health – Key milestones include first subject dosed in Phase 1 KUR-101, launch of drug discovery engine Invyxis, initiation of Psyber usability study in patients and COMPASS’ end of Phase 2 FDA meeting – Ended the first quarter with $335 million cash, maintaining atai’s position as a well-funded, leading mental health company Video int
In this article we will discuss some new stock picks of Cathie Wood’s hedge fund. You can skip this part and go directly to see the top 5 New Stock Picks of Cathie Wood in 2022. Despite huge criticism and losses, Cathie Wood’s hedge fund ARK Investment continues to attract investors amid promises of future […]
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued yesterday under the headline "atai Life Sciences to Announce First-Quarter 2022 Financial Results" by atai Life Sciences N.V. (Nasdaq: ATAI), please note the first and second paragraphs, which contained statements referencing the 2022 IR financial results posting and executives on the video interview, as well as forward-looking statements, have been modified. The corrected release follows: atai Life Sciences N.V. (Nasdaq: ATAI) (“ata